Table 1 Clinicopathologic and trial characteristics.
RTOG-9202 | RTOG-9408 | RTOG-9413 | RTOG-9910 | RTOG-0126 | Combined | |
|---|---|---|---|---|---|---|
Number of Patients | 1180 | 1719 | 695 | 976 | 1084 | 5654 |
White | 1004 | 1312 | 481 | 769 | 937 | 4503 |
Hispanic | 18 | 48 | 23 | 23 | 0 | 112 |
African American | 147 | 334 | 173 | 166 | 112 | 932 |
Asian | 4 | 12 | 1 | 11 | 12 | 40 |
Other Race | 1 | 10 | 11 | 6 | 9 | 37 |
Unknown Race | 6 | 3 | 6 | 1 | 14 | 30 |
Number of Pathology Slides | 3188 | 5472 | 2104 | 3075 | 2365 | 16204 |
Number of Clinical Variables | 53 | 69 | 71 | 60 | 62 | − |
Therapy Randomization | RTS vs. RTL | RT vs. RTS | RTS 2 × 2a | RTS vs. RTM | RT vs. RT + | − |
Patient Risk Groups | Inter. | High | Low | Inter. | High | Inter. | High | Inter. | High | Inter. | Low | Inter. | High |
Primary Endpoint | Disease-free Survival | Overall Survival | Progression-free Survival | Prostate Cancer-specific Mortality | Overall Survival | − |
Median Follow-up for Censored Patients (Years) | 17.4 | 15.1 | 13.7 | 9.3 | 13.2 | 11.4 |
No. Patients Died | 944 | 1154 | 504 | 297 | 505 | 3404 |
Trial Accrual Dates | 1992–1995 | 1994–2001 | 1995–1999 | 2000–2004 | 2002–2008 | 1992–2008 |
